Close Menu
Business Voice NowBusiness Voice Now
    Facebook X (Twitter) Instagram
    Business Voice NowBusiness Voice Now
    Subscribe
    • Markets
      • IPO
      • Market News
    • Business
      • FMCG
      • Retail
      • Quick Commerce
      • Startups
    • Healthcare
    • Technology
    • Energy
    • Voices
      • Entrepreneur – CXO Stories
      • Corporate Office story
    • E Magazine
      • Year 2026
        • November 2026
        • October 2026
        • September 2026
        • August 2026
        • July 2026
    Business Voice NowBusiness Voice Now
    Home»Business»Wockhardt observes The World Diabetes Day, continuing to serve diabetic patients with quality medicines at affordable prices
    Business

    Wockhardt observes The World Diabetes Day, continuing to serve diabetic patients with quality medicines at affordable prices

    By November 14, 2022No Comments2 Mins Read
    Share Facebook Twitter Pinterest LinkedIn Tumblr Email
    Follow Us
    Google News Flipboard Threads
    Share
    Facebook Twitter LinkedIn Pinterest Email

    India, November 14: Diabetes is a metabolic disorder of multiple aetiology characterized by chronic hyperglycemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action or both. International Diabetes Federation (IDF) have estimated that the prevalence of diabetes worldwide is 10.5%. If current trends continue, 783 million adults will have diabetes by 2045. India is home to 74.2 million diabetics, second highest in the world.

    World Diabetes Day is the global awareness campaign focusing on diabetes mellitus and is held on 14th November each year. Millions of patients worldwide do not have access to diabetes care and many of them require ongoing care to manage diabetes and avoid complications.

    One of the fundamental components of diabetes care includes access to insulin that 73 million Indians must take daily to manage their diabetes & prevent complications. However, even today affordability of insulin still remains a challenge which is one of the major reason for non-adherence. It is observed that because of non-adherence 45% of patients with T2DM fail to achieve adequate glycemic control (HbA1c <7%) and this may result in the complications of the disease observed in the long run. Hence, providing access to insulin therapy by addressing the challenges of non-affordability and accessibility becomes very important for management of diabetes.

    Wockhardt, India’s one of the leading pharmaceutical company has been a pioneer in development of indigenous insulin. Wockhardt was the 1st Indian company to manufacture Insulin in India and has been helping Indian patients access the insulin at an affordable price for last 20 years. Moreover, Wockhardt is the only company that introduced the concept of 50% extra insulin in its insulin range of products – WOSULIN (human insulin) and GLARITUS (insulin glargine).

    After launching quality bio similar insulin’s Glaritus and Wosulin which have been helping Indian diabetes patients to break the affordability barrier, Wockhardt has forayed into Sitagliptin segment with Sitawok which is one of the most economical Sitagliptin brand with global quality.

    We at Wockhardt believe that quality medicine is not a privilege but a necessity, therefore it is important to make quality medicines at affordable prices and we are striving to achieve the same every day and help life win!

    If you have any objection to this press release content, kindly contact pr.error.rectification@gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.

    Business
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    Inspiring Infosys’ SellWell Platform to Highlight Technology-Driven E-commerce Solutions at Tech Expo Gujarat 2026

    November 18, 2026

    UNISOC to Deploy Smart Meters in India, partnering with Neoway and Genus, Deepening Global Energy Digitalization

    November 18, 2026

    Chandan Healthcare H1 FY27 Growth PAT Soars 257% YoY to Rs 25.37 Cr, EBITDA Jumps 67% YoY to Rs 40.31 Cr

    November 18, 2026

    Comments are closed.

    Recent Post
    • Irfan Pathan and Adah Sharma Grace the Launch of Youth Cricket League’s YCLT10
    • From Military Service to Social Change: Ramesh Sangle Explores Nation-Building in BRIGADE
    • How Officebing Plans Workplaces Around Different Functions
    • Inspiring Infosys’ SellWell Platform to Highlight Technology-Driven E-commerce Solutions at Tech Expo Gujarat 2026
    • Manav’s ‘Bardic Voices: Where the Horizon Meets, the Magic Begins’ Explores Memory, Humanity, and the Search for Meaning
    • Glen Industries Limited Reports H1 FY27 Results
    • Spreading Bliss Foundation Supports Children in Orphanage
    • Mastertrust Launches mtAlgoZ to Enhance Digital Trading with Automated Strategy Building and Execution

    Type above and press Enter to search. Press Esc to cancel.